AnalystBook Research · Company Intelligence

Core Laboratories Inc. /DE/

CLBNYSE

Built from Core Laboratories Inc. /DE/'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Core Labs held revenue flat, but FCF and earnings slipped.

The read at a glance✓ Audited against SEC data
  • Business mixReservoir and production servicesNote
  • Revenue$526.5M, +0.5%Note
  • Net income$29.7M, -5.5%Watch
  • FCF$25.8M, -42.0%Watch
  • Debt$113.0M, -11.7%OK
  • Altman/Beneish/EQGrey Z; clean M/EQNote
  • InsidersNo purchases or salesNote

Business

Core Laboratories provides reservoir description and production enhancement services and products to oil and gas clients.

Where the revenue comes from

Fiscal 2025, as Core Laboratories Inc. /DE/ reports it. History and quarterly detail are in the app.

  • Operating Segment Reservoir Description$347.7M
  • Operating Segment Production Enhancement$178.8M

Leadership changes

From Core Laboratories Inc. /DE/'s own filings, the day they're filed.

  • Kevin Daniels · Chief Accounting Officer · departureeff. 2024-03-21

Latest filings

  • 8-K · Company announcement2026-08-25
  • 10-Q · Quarterly report2026-07-30
  • 8-K · Company announcement2026-07-29
  • 8-K · Company announcement2026-05-13
  • 10-Q · Quarterly report2026-05-01
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Core Laboratories Inc. /DE/, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.